These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21347736)

  • 1. Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients.
    Antignac M; Fernandez C; Barrou B; Roca M; Favrat JL; Urien S; Farinotti R
    Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):25-33. PubMed ID: 21347736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation.
    Fukudo M; Yano I; Fukatsu S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
    Clin Pharmacokinet; 2003; 42(13):1161-78. PubMed ID: 14531726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
    Brooks E; Tett SE; Isbel NM; Staatz CE
    Clin Pharmacokinet; 2016 Nov; 55(11):1295-1335. PubMed ID: 27138787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients.
    Willis C; Staatz CE; Tett SE
    Ther Drug Monit; 2003 Apr; 25(2):158-66. PubMed ID: 12657909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients.
    Methaneethorn J; Lohitnavy M; Onlamai K; Leelakanok N
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):105-116. PubMed ID: 34817826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.
    Størset E; Holford N; Hennig S; Bergmann TK; Bergan S; Bremer S; Åsberg A; Midtvedt K; Staatz CE
    Br J Clin Pharmacol; 2014 Sep; 78(3):509-23. PubMed ID: 25279405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.
    Antignac M; Barrou B; Farinotti R; Lechat P; Urien S
    Br J Clin Pharmacol; 2007 Dec; 64(6):750-7. PubMed ID: 17425625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.
    Zhao CY; Jiao Z; Mao JJ; Qiu XY
    Br J Clin Pharmacol; 2016 May; 81(5):891-907. PubMed ID: 26574188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
    Liu S; Chen RX; Li J; Zhang Y; Wang XD; Fu Q; Chen LY; Liu XM; Huang HB; Huang M; Wang CX; Li JL
    Acta Pharmacol Sin; 2016 Sep; 37(9):1251-8. PubMed ID: 27498776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
    Staatz CE; Willis C; Taylor PJ; Tett SE
    Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.
    Chen YH; Zheng KL; Chen LZ; Dai YP; Fei JG; Qiu J; Li J
    Transplant Proc; 2005 Dec; 37(10):4246-50. PubMed ID: 16387090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
    Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
    Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
    Benkali K; Prémaud A; Picard N; Rérolle JP; Toupance O; Hoizey G; Turcant A; Villemain F; Le Meur Y; Marquet P; Rousseau A
    Clin Pharmacokinet; 2009; 48(12):805-16. PubMed ID: 19902988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children.
    Zhao W; Maisin A; Baudouin V; Fakhoury M; Storme T; Deschênes G; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2013 May; 69(5):1181-5. PubMed ID: 23208323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended-release tacrolimus preparation.
    El-Nahhas T; Popoola J; MacPhee I; Johnston A
    Clin Transl Sci; 2022 Jan; 15(1):70-78. PubMed ID: 34780122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.